Aditxt (ADTX) Stock Has Surged Higher, Here’s Why

Life sciences company Aditxt (NASDAQ:ADTX) stock has surged higher before the US market open today, sending its share price as high as 80%…

It has fallen slightly since and is now trading at $6.69, Up by 70.23%, but what has caused its surge…

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Well, the company issued a press release earlier today introducing AditxtScore which is used to detect antibodies against SARS-CoV-2 and can be used to detect COVID-19 antibodies.

The company said that that it can be used to “detect and differentiate various antibody isotypes (IgG, IgM, IgA) against multiple SARS-CoV-2 antigens (e.g. RBD, S1, NP) simultaneously in a single reaction.”

While the most used platform, ELISA can only detect one antibody isotype against one antigen at a time.

They went on to say that false positive and false negative tests are significantly reduced with its antibody profiling system, and they feel it will be a valuable tool to evaluate COVID-19 immune responses.

Aditxt now plans to file for an Emergency Use Authorisation (EUA) followed by a 510(K) application with the FDA by the end of the third quarter.

Harpreet Sandhu, Chief Executive Officer of Stanford Blood Center (SBC), commented, “The AditxtScore for COVID-19 has the potential to be a game changer for our industry. AditxtScore for COVID-19 is a multiplexed platform that has shown tremendous speed and accuracy, which is extremely critical for meeting the ongoing COVID-19 challenge.”